ZinClear Photostable Protection. Sunscreen performance after 3 hours in Australian sun (average UV load), measured in Perth, Western Australia

Transcription

1 ANO Presentation ADVANCE NANOTEK LTD ZinClear Photostable Protection Sunscreen performance after 3 hours in Australian sun (average UV load), measured in Perth, Western Australia IN-VITRO SPF (COLIPA METHOD) ZinClear IM based formula 5 PRE IRRADIATION POST IRRADIATION Chemical absorber based formula 24 various skin cancer procedures For me it s not just business, it s PERSONAL Managing Director Geoff Acton

2 Anticipated Net profit Increase Due to Expected Reinstatement of Deferred Tax Assets* Net Profit ($) Year Subject to 3 years continuous trading profit. Anticipated franked dividends to commence In FY23. 1

3 Total Annual Sales Revenue by Product Category ($) Total Annual Sales Revenue by Product Category ($) $8,, $7,4,. $7,, $6,, $5,5,176 $6,,. Revenue Growth ($) $5,, $4,, $3,, $4,284,371 $3,273,758 $3,723,936 $4,58,86 $3,892,219 $2,937,647 $3,565,126 $4,521,646 $4,75,979 $3,893,236 $1,949,324 $2,, $1,, $1,1,613 $1,774,612 $1,121,213 $327,93 $445,667 $1,111,94 $1,4, $ Dec 217 Zinclear Alusion Total Sales 218/19 Total sales increase of 12.8% compared to December 216. Further sales increases expected in FY18 & FY19 from MERCK. The new decanter (part of the qualified audit opinion on assets by the previous auditors) has been commissioned and will increase production capacity of Alusion. 2

4 ANO Total Operating Costs (Including Wages) ($) $3,4, $3,282,48 ANO Total Operating Costs (Incuding Wages) ($) $3,2, $3,, $2,875,851 Total Operating Cost ($) $2,8, $2,6, $2,592,22 $2,41,616 $2,6, $2,45, $2,4, $2,2, $2,36,98 $2,, Dec Dec Delays in the transition to 112 & the use of double shifts to cater for production increase has led to increases in total operating costs. Expect to reduce them in FY18/19. The contract manufacturing arrangement in the US should commence May 218. The combined manufacturing facility in Australia will also lead to significant cost savings in FY18/19. 3

5 Wages as a % of Sales Revenue 35.% 3.% 3.27% 27.14% Wages (%) 25.% 2.% 21.33% 21.82% 15.% 13.63% 1.% 13.7% Dec Dec % Slight increase in wages due to increase in production with double shifts. Expected to fall in FY18/19. 4

6 Travel Expense as a % of Sales Revenue 5.% 4.5% 4.29% 4.11% 4.45% 4.% 3.5% Travel Expense (%) 3.% 2.5% 2.% 1.48% 1.5% 1.17% 1.2% 1.%.5%.54%.% Dec Dec Have increased the distributor and chemist network without significant travel. Travel limited to inspecting new manufacturing facilities and signing significant agreements with customers, suppliers and manufacturers. New approach involving local distributors has replaced travel to major international trade shows. 5

7 Number of Distributors and Resellers Number of Distributors or Resellers Dec Distributors Resellers GLOBAL DISTRIBUTION NETWORK Connell Brothers India India (reseller) Connell Brothers Malaysia Malaysia Deveraux Specialities LLC USA ENS Beauty Group South Korea Heterochem UK/Ireland Manuchar- Indonesia/ Philippines Neochem Gmbh Germany Pachem Distribution Canada Para Chemie Sina Iran Pure Ingredients - New Zealand Unipex France/ Belgium TARGETS Spain Portugal Italy Sweden Norway Denmark Finland Estonia Latvia Lithuania Netherlands Greece Czech Republic Turkey Japan China Sri Lanka Taiwan 6

8 ANO R&D Costs and Number of Formulations and Products Being Developed 6 16 Number of Formulations Developed or being developed RnD Costs ($) Dec Number of Formulations Developed or being developed R&D Costs 41 end formulations in various stages of development including sunscreens, lipsticks, after shave lotions, day repair creams, foundations, anti-acne creams, and facial masks. Different plastic film compositions, 2 battery compositions, and ZNO material for 3D printing in ceramics (these are highly speculative). In addition we have completed full testing on new precursor suppliers. 7

9 Number of Chemists Supporting our Products Number of Chemists Supporting our products Number of Chemists Dec External Chemists Supporting our products Internal Chemists Supporting our products The unique nature of our product and difficulties in product development requires barriers to substitution ANO is investing in this product formulation and R&D to support our small customers who do not have the resources to develop end formulations. Looking forward to releasing our own ZinXation range of products in 218/219 ZinXation will be much more valued by the current Board than Invisible Zinc was by the original board who sold the brand (now worth > $4 million) without agreements and our active ingredient being used in the products. 8

10 Number of New Patents Developed Number of New patents developed Dec Dec Patent renewals are not included as the process is ongoing and the number of renewals will vary depending on expiry dates. 9

11 ANO Share Price.7 ANO Share Price

12 ZinClear IM Optimized for Transparency with Index Match Technology ZinClear XP >37nm Critical Wavelength Overview UV Absorbers Portfolio PRODUCT NAME ZinClear IM 5JJ ZinClear IM 5CCT ZinClear IM 5AB ZinClear IM 55L7 ZinClear XP 65COCO INCI Zinc Oxide (and) Simmondsia Chinensis (Jojoba) Seed oil (and) Glyceryl Isostearate (and) Polyhydroxystearic Acid Zinc Oxide (and) Caprylic/Capric Triglyceride (and) Polyhydroxystearic Acid (and) Glyceryl Isostearate Zinc Oxide (and) C12-15 Alkyl Benzoate (and) Polyhydroxystearic Acid (and) Isostearic Acid Zinc Oxide (and) Neopentyl Glycol Diheptanoate (and) Glyceryl Isostearate (and) Polyhydroxystearic Acid (and) Cetyl PEG/PPG-1/1 Dimethicone Zinc Oxide (and) Coco-Caprylate/ Caprate (and) Polyglyceryl-3 Polyricinoleate (and) Isostearic Acid RANGE OF ABSORPTION ACTIVE % UVA & UVB 5 UVA & UVB 5 UVA & UVB 5 UVA & UVB 55 UVA & UVB 65 ZinClear XP Zinc Oxide UVA & UVB 1 Ac (nm) VISCOSITY NATURAL Broad spectrum 37nm Broad spectrum 37nm Broad spectrum 37nm Broad spectrum 37nm Broad spectrum > 37nm Broad spectrum > 37nm Pourable Pourable Pourable Pourable Pourable Free flowing powder ZinClear Photostable Protection Sunscreen performance after 3 hours in Australian sun (average UV load), measured in Perth, Western Australia IN-VITRO SPF (COLIPA METHOD) PRE IRRADIATION POST IRRADIATION ZinClear IM based formula Chemical absorber based formula 11

13 ZinClear Absorbance of UVB and UVA 2 UVB UVA XP 65COCO 1.5 ZinClear IM ABSORBANCE 1.5 Common products currently used in USA Competitor Zinc Oxide Competitor Titanium Dioxide 1 Competitor Titanium Dioxide WAVELENGTH (nm) 12

14 ZinClear IM is Optimized for Transparency 1 UVA VISIBLE LIGHT TOTAL TRANSMITTANCE (%) XP 65COCO ZinClear IM Common products currently used in USA Competitor Zinc Oxide Competitor Titanium Dioxide 1 Competitor Titanium Dioxide WAVELENGTH (nm) 13

15 Disclaimer Management of Advance NanoTek Ltd (ABN ) and its subsidiaries (collectively ANO ) has made every effort to ensure the accuracy of information contained in this presentation. The presentation has been prepared based on information available prior to the date of this presentation. No responsibility or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Advance NanoTek, its related bodies corporate or any of its directors, employees, agents or advisers accept any liability for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it, including, without limitation, any liability arising from fault or negligence on the part of Advance NanoTek, its related bodies corporate or any of its directors, employees, agents or advisers. The material contained in this presentation is for information purposes only and does not constitute financial product advice. The information contained in this presentation has been prepared without taking into account the investment objectives, financial situation or particular needs of any particular person. Before making any investment decision, you should consider, with or without the assistance of a financial adviser, whether an investment is appropriate in light of your particular investment needs, objectives and financial circumstances. Nothing in this presentation is a promise or representation as to the future. Statements or assumptions in this presentation as to future matters may prove to be incorrect and the differences may be material. 14